BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Wockhardt’s Miqnaf Gains CDSCO Approval for CABP Treatment

Synopsis:

Wockhardt Ltd’s Miqnaf (nafithromycin), approved by CDSCO for CABP, is an ultra-short course antibiotic targeting drug-resistant pathogens. Despite the news, Wockhardt share price declined by 0.88%.

Wockhardt news today

Pharmaceutical company Wockhardt Ltd has received approval from the Central Drugs Standard Control Organization (CDSCO) for Miqnaf (nafithromycin), a novel treatment for Community-Acquired Bacterial Pneumonia (CABP) in adults. The antibiotic offers an ultra-short course regimen of once-a-day dosage for three days, targeting multi-drug resistant (MDR) pathogens.

Also read: Biocon Gets China NMPA Approval for Tacrolimus Capsules

WOCKHARDT LIMITED

Trade

1397.6-67.59 (-4.61 %)

Updated - 25 April 2025
1472.50day high
DAY HIGH
1375.10day low
DAY LOW
530473
VOLUME (BSE)

Key Takeaways

  • Innovative Regimen: Ultra-short, three-day course for improved patient compliance.

  • Target Pathogens: Effective against MDR bacteria like S. pneumoniae and H. influenzae.

  • Clinical Trials: Tested in the US, Europe, South Africa, and India.

  • India’s Disease Burden: India accounts for 23% of global CABP cases.

Also read: Avenue Supermarts Reports 17.5% Revenue Growth in Q3 FY25

A New Era for Macrolide-Based Antibiotics

Miqnaf is the first macrolide-based antibiotic introduced in India in nearly 30 years, addressing a critical gap in CABP treatment. It is designed to combat antibiotic-resistant strains, reducing the need for hospitalisation in severe cases. This aligns with efforts to mitigate India’s growing antibiotic resistance crisis, which significantly impacts the treatment of respiratory infections.

Table: Key Features of Miqnaf

Feature

Details

Treatment Duration

3 days, once daily

Target Pathogens

MDR strains, including S. pneumoniae

Clinical Studies

Conducted across US, Europe, and India

Disease Focus

CABP and other respiratory infections

Market Launch and Impact

Wockhardt plans to launch Miqnaf in the Indian market within a few months. With India bearing a significant global disease burden for CABP, Miqnaf is expected to play a pivotal role in improving treatment outcomes.

The approval of Miqnaf signifies a significant advancement in CABP treatment, addressing antibiotic resistance and improving compliance. Despite this milestone, Wockhardt share price declined by 0.88%, closing at ₹1,445.75.

Also read: IRFC Partners REMCL to Fund Renewable Energy for Railways

Do you have a trading account app or demat account app?

You can open an account with Bajaj Broking in minutes.

Download the Bajaj Broking app now from Play Store or App Store.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

9.5 lakh+ Users

icon-with-text

4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4400+ Cr MTF Book

icon-with-text